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OBJECTIVES This study was designed to determine the relevance of a proposed classification for advanced
heart failure (HF). Profiles based on clinical assessment of congestion and perfusion at the
time of hospitalization were compared with subsequent outcomes.
BACKGROUND Optimal design of therapy and trials for advanced HF remains limited by the lack of simple
clinical profiles to characterize patients.
METHODS Prospective analysis was performed for 452 patients admitted to the cardiomyopathy service
at the Brigham and Women’s Hospital with a diagnosis of HF. Patients were classified by
clinical assessment into four profiles: profile A, patients with no evidence of congestion or
hypoperfusion (dry-warm, n  123); profile B, congestion with adequate perfusion (wet-
warm, n  222); profile C, congestion and hypoperfusion (wet-cold, n  91); and profile L,
hypoperfusion without congestion (dry-cold, n  16). Other standard predictors of outcome
were included and patients were followed for the end points of death (n  117) and death or
urgent transplantation (n  137) at one year.
RESULTS Survival analysis showed that clinical profiles predict outcomes in HF. Profiles B and C
increase the risk of death plus urgent transplantation by univariate (hazard ratio [HR] 1.83,
p  0.02) and multivariate analyses (HR 2.48, p  0.003). Moreover, clinical profiles add
prognostic information even when limited to patients with New York Heart Association
(NYHA) class III/IV symptoms (profile B: HR 2.23, p  0.026; profile C: HR 2.73, p 
0.009).
CONCLUSIONS Simple clinical assessment can be used to define profiles in patients admitted with HF. These
profiles predict outcomes and may be used to guide therapy and identify populations for future
investigation. (J Am Coll Cardiol 2003;41:1797–804) © 2003 by the American College of
Cardiology Foundation
As new treatments for heart failure (HF) emerge, there is an
urgent need to identify the appropriate patient for each
therapy. The spectrum of patients hospitalized with ad-
vanced to severe HF presents particular challenges. In
clinical trials, these patients range from those for whom
routine use of intravenous inotropic therapy has no impact
on outcome (1) to those who need a left ventricular assist
device (LVAD) to improve their annual survival from 25%
to 52%, despite palliative intravenous inotrope use in 72%
(2).
Indicators of disease severity have been used to stratify
patients. Some precise parameters such as peak oxygen
consumption are complex to obtain and most useful in
moderate rather than acutely decompensated HF. Other
indicators such as the New York Heart Association
(NYHA) symptom classification are subjective and difficult
to separate from concomitant disease conditions. Many
laboratory values such as neurohormonal markers and renal
indices, although useful in large populations, do not provide
clear thresholds for the intensification of therapy in an
individual patient. Therefore, most physicians rely upon the
clinical history and physical examination to assess and guide
therapy in this patient population.
In 1976, Forrester et al. (3) demonstrated that among
patients who had an acute myocardial infarction (AMI), the
physical examination identified four hemodynamic profiles
defined by Swan-Ganz catheterization. These profiles were
based on the presence or absence of congestion (pulmonary
capillary wedge pressure [PCWP]  or 18 mm Hg) and
adequacy of perfusion (cardiac index [CI] 2.2 l/min/m2).
Profile I represented no congestion or hypoperfusion; profile
II, congestion without hypoperfusion; profile III, hypoper-
fusion without congestion; and profile IV, both congestion
and hypoperfusion. Furthermore, both the clinical and
invasive hemodynamic profiles predicted short-term sur-
vival, with increased mortality when congestion was present
and even worse outcomes when both congestion and hypo-
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perfusion were evident (3). Physical findings (such as rales
and peripheral edema) used to determine profiles after an
AMI are often inadequate for the detection of elevated
filling pressures in chronic HF (4). However, other compo-
nents of the clinical evaluation (such as orthopnea and
proportional pulse pressure) correlate well with hemody-
namics in chronic HF (4). It remains to be shown whether
definition of hemodynamic profiles, based on the history
and physical examination, provides meaningful distinction
among patients with chronic HF.
Our study tested the hypothesis that the four clinical
profiles, determined by evidence of congestion and adequacy
of perfusion on clinical examination, define prognostic
categories in patients admitted with a history of HF.
METHODS
Patient population. This analysis included 452 consecu-
tive hospitalized patients referred to the cardiomyopathy
service at Brigham and Women’s Hospital between Novem-
ber 1996 and July 1999 with a new or prior diagnosis of HF.
Among these patients, the primary admitting diagnosis was
decompensated HF in 49%, arrhythmia in 12%, angina in
12%, elective transplant evaluation for chronic HF in 17%,
and other issues, such as infection, in 6%. Baseline charac-
teristics of the patient population are shown in Table 1.
Patient information was obtained from the medical record
and the Social Security Death Index. Brigham and Wom-
en’s Hospital’s Human Research Committee approved this
study.
Assessment of clinical profiles. Physicians (faculty or
fellows) on the cardiomyopathy service evaluated and pro-
spectively classified patients within 24 h of admission into
four hemodynamic profiles based on the clinical examina-
tion. Physicians also prospectively assessed NYHA func-
tional class based on the patients’ reported functional
limitation. The clinical profiles were defined by: 1) the
absence or presence of signs of congestion, and 2) evidence
suggesting adequate or inadequate perfusion (Fig. 1). Indi-
cations of congestion included a recent history of orthopnea
and/or physical exam evidence of jugular venous distention,
rales, hepatojugular reflux, ascites, peripheral edema, left-
ward radiation of the pulmonic heart sound, or a square
wave blood pressure response to the Valsalva maneuver.
Compromised perfusion was assessed by the presence of a
narrow proportional pulse pressure ([systolic  diastolic
blood pressure]/systolic blood pressure25%), pulsus alter-
nans, symptomatic hypotension (without orthostasis), cool
extremities, and/or impaired mentation. Physicians synthe-
sized the presence or absence of any or all of these signs to
make a subjective assessment of the patients’ volume and
perfusion status. Physicians were not required to justify their
assignment of clinical profile, nor was their classification
verified or altered by the authors of this study.
Survival estimates. Patients were followed for at least one
year after the index admission with a mean follow-up of 18
 13 months. Survival for each profile was estimated for the
end points of: 1) death without transplantation, and 2)
either death without transplantation or urgent transplanta-
Abbreviations and Acronyms
AMI  acute myocardial infarction
CI  cardiac index
ESCAPE  Evaluation Study of Congestive Heart
Failure and Pulmonary Artery
Catheterization
HF  heart failure
HR  hazard ratio
LVAD  left ventricular assist device
NYHA  New York Heart Association
PCWP  pulmonary capillary wedge pressure
REMATCH  Randomized Evaluation of Mechanical
Assistance for the Treatment of
Congestive Heart Failure
SOLVD  Studies Of Left Ventricular Dysfunction
UNOS  United Network of Organ Sharing
Table 1. Baseline Characteristics of the Patient Population
Characteristics Values
Total patients, n 452
Men/women, n/n (%,%) 313/139 (69/31)
Mean age  SD, yrs 55.4  14.2
Mean ejection fraction  SD, % 25.8  11.8
Etiology of heart failure
Ischemic cardiomyopathy, n (%) 222 (49)
Dilated cardiomyopathy, n (%) 118 (26)
Other, n (%) 112 (25)
Medications on admission
ACEI or ARBs, n (%) 331 (73)
Digoxin, n (%) 301 (67)
Diuretics, n (%) 362 (80)
Beta-blockers, n (%) 116 (26)
ACEI  angiotensin-converting enzyme inhibitors; ARB  angiotensin receptor
blockers.
Figure 1. Schematic for assessment of clinical profiles. Congestion was
assessed by the presence of orthopnea, jugular venous distention, rales,
hepatojugular reflux, ascites, peripheral edema, leftward radiation of the
pulmonic heart sound, or a square-wave blood pressure response to the
Valsalva maneuver. Compromised perfusion was assessed by the presence
of a narrow proportional pulse pressure, pulsus alternans, symptomatic
hypotension (without orthostasis), cool extremities, and/or impaired men-
tation.
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tion at one year. Urgent transplantation was defined as
United Network of Organ Sharing (UNOS) status 1 (re-
ceiving intravenous inotropic or mechanical support up
until the time of transplantation). The follow-up rate was
99.5%.
Statistical analysis. All data are expressed as mean  SD.
Comparisons of parameters between profiles were made by
Fisher’s exact test or one-way ANOVA, followed by a
Bonferroni correction for multiple comparisons. A value of
p  0.08 was considered significant for individual compar-
isons. The overall p values reflecting trends between groups
are reported rather than p values for individual comparisons.
Survival curves were derived by the Kaplan-Meier method
and compared using the log-rank test, followed by a
Bonferroni correction for multiple comparisons. Profile L
was excluded because of the small number of events in this
category. Patients who underwent UNOS 2 transplant were
censored at transplantation, as were patients who were alive
without a transplant at the end of the follow-up period. A
value of p  0.02 was considered significant for individual
comparisons. The prognostic value of each variable was
tested by univariate Cox proportional hazards regression
analysis. The prognostic value of the clinical profiles relative
to other predictors identified by the univariate analysis was
compared using a multivariate model. A value of p  0.05
was considered statistically significant.
RESULTS
Comparison of patient characteristics by clinical profile.
Of the 452 patients, 123 (27%) were classified as profile A
(dry-warm), 222 (49%) as profile B (wet-warm), 91 (20%) as
profile C (wet-cold), and 16 (4%) as profile L (dry-cold).
The limited number of patients with profile L did not allow
meaningful comparison of this category. Nonetheless, pa-
tients in all four profiles were statistically similar with regard
to age, gender, etiology and duration of HF, and medication
use other than beta-blockers at the time of admission (Table
2). Other known predictors such as left ventricular ejection
fraction (5), NYHA functional class (6), resting heart rate
(7), systolic blood pressure (8), serum sodium (9), and serum
creatinine (10,11) suggested that patients with profile C
(wet-cold) had more advanced HF than those with profile B
(wet-warm), who in turn had more severe disease than
patients with profile A (dry-warm) (Table 2). Only 40% of
patients had peak oxygen consumption measured within six
months of hospitalization. The mean peak oxygen con-
sumption for each clinical profile was within 10 to 14
ml/kg/min, with no significant differences between the
distinct clinical profiles (p  0.244).
Although right heart catheterization was performed in
only 50 of the 452 patients within 24 h of admission, it
suggested that clinical profiles reflect invasive hemodynam-
ics (Table 2). Patients with profiles B and C had higher
PCWP than patients with profile A (p  0.0001), whereas
profile C tended to have lower CI than profiles A and B (p
 0.07).
Prognosis by clinical profile. Of the 452 patients, 117
(26%) died without transplantation at one year. An addi-
tional 42 (9%) were transplanted within one year, 20 of who
were listed as UNOS 1 at the time of transplantation.
Kaplan-Meier survival curves for the end-points of death
and death plus urgent transplantation according to the
clinical profiles are shown in Figure 2. Patients with profile
C had a lower survival than profile B (p  0.01). Both
profiles B and C conferred a significantly higher mortality
than profile A (p  0.01). Limited patient numbers with
profile L precluded meaningful statistical analysis of this
category.
Table 2. Baseline Characteristics of Patients According to the Clinical Profile
Characteristics
Clinical Profiles
p ValuesA (n  123) B (n  222) C (n  91) L (n  16)
Age, yrs 55  14 56  15 55  13 50  13 0.30
Male gender, % 73 67 71 56 0.41
Ischemic cardiomyopathy, % 53 46 53 44 0.53
Time since first diagnosis, months 14  22 22  32 11  17 27  46 0.14
Medications
ACEI or ARB, % 78 74 65 75 0.19
Digoxin, % 68 68 64 56 0.72
Diuretics, % 80 82 76 81 0.66
Beta-blockers, % 35 23 19 22 0.04
Ejection fraction, % 28.2  11.0 26.3  12.9 21.5  9.5 23.6  7.3 0.0004
NYHA functional class 2.3  0.9 3.1  0.7 3.5  0.8 2.9  0.9  0.0001
Resting heart rate, beats/min 81  16 88  18 91  21 81  20 0.0004
Systolic blood pressure, mm Hg 116  23 114  21 103  17 101  15  0.0001
Serum sodium, mEq/l 138  4 137  5 136  5 137  5 0.01
Serum creatinine, mg/dl 1.3  1.0 1.4  0.8 1.5  1.0 1.3  1.0 0.40
PCWP (n  53), mm Hg 15.6  7.9 26.7  6.0 32.3  6.9 30.3  4.0  0.0001
CI (n  50), mm Hg 2.3  0.3 2.1  0.6 1.9  0.7 1.6  0.5 0.07
*Plus-minus values are means  SD.
ACEI angiotensin-converting enzyme inhibitors; ARB angiotensin receptor blockers; CI cardiac index; NYHANew York Heart Association; PCWP pulmonary
capillary wedge pressure.
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Univariate and multivariate predictors of mortality.
Univariate analysis revealed that patients with profiles B
(hazard ratio [HR] 2.10, p  0.003) and C (HR 3.66, p 
0.001) were at significantly higher risk for the combined
outcome of death or urgent transplantation than patients
with profile A (Table 3). Additionally, other known predic-
tors including NYHA class, age (6), ischemic etiology of
HF (8,12), serum sodium (9), serum creatinine (10,11), and
systolic blood pressure (8) were all associated with an
increased risk of death or urgent transplantation at one year
in the univariate model (Table 3).
Among the characteristics identified by univariate
analysis, profiles B (HR 1.83, p  0.02) and C (HR 2.48,
p  0.002) remained independent predictors of mortality
or urgent transplantation in the multivariate analysis (Table
4). Age, ischemic cardiomyopathy, and serum creatinine
also remained unfavorable in the multivariate analysis
(Table 4).
Prognosis by clinical profile and NYHA class. In order to
assess whether clinical profiles provided any additional
prognostic information beyond functional class, the patient
population was further stratified into those with NYHA
class I/II (n  124) and class III/IV (n  326) symptoms.
The majority of patients with NYHA class I/II symptoms
had profile A (71/124), followed by profile B (39/124) on
clinical assessment. There were only 23 deaths or urgent
transplants among NYHA class I/II patients, making the
numbers too small for statistical analysis. In contrast,
profiles B (182/326) and C (81/326) constituted most of the
patients with NYHA class III/IV symptoms. However, a
substantial number of patients describing severe symptoms
(NYHA class III/IV) were found to have profile A (51/326)
on clinical evaluation. Among the patients with NYHA
class III/IV symptoms, survival analysis for the combined
end point of death or urgent transplantation (n  113)
revealed that profile C tended to confer a worse prognosis
than profile B (p  0.04, significance level 0.02 for multiple
comparisons), which in turn had a worse outcome than
profile A (p  0.015) (Fig. 3). Multivariate analysis re-
stricted to patients with NYHA class III/IV symptoms
revealed that both profiles B (HR 2.23, p  0.026) and C
(HR 2.73, p 0.009) delineate patients at increased risk for
Figure 2. Kaplan-Meier survival curves according to the clinical profiles. The end points were one-year mortality (Panel A) and one-year mortality plus
urgent transplantation (Panel B). In both panels, profile C conferred the worst outcomes, followed by profile B, which was worse than profile A. Profile
L had too few patients for meaningful statistical analysis. Panel A: *p  0.002 for profile A versus profile B, †p  0.008 for profile B versus profile C,
‡p  0.001 for profile A versus profile C. Panel B: *p  0.002 for profile A versus profile B, †p  0.005 for profile B versus profile C, ‡p  0.001 for
profile A versus profile C.
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adverse outcomes, whereas profile A identifies those who
may do well despite severe symptoms (Table 4).
DISCUSSION
In this article we used clinical assessment, based on the
admission physical examination, to define four simple pro-
files in hospitalized patients with a history of HF. These
profiles, which are easily assessed at the bedside, predict
outcomes and provide prognostic information in addition to
that obtained from other established indices. These clinical
profiles may be used to guide therapy and may provide a
means for the identification of suitable patient populations
for trials of future therapies.
Basis for the prognostic value of clinical profiles. In this
cohort of hospitalized patients with HF, clinical profiles
distinguish between populations that reflect established
prognostic indicators including ejection fraction (5), NYHA
class (6), resting heart rate (7), systolic blood pressure (8),
and serum sodium (9). Additionally, both univariate and
multivariate analyses demonstrate that clinical profiles are
independent predictors of mortality and urgent transplan-
tation in patients admitted with a history of HF. In fact,
these data suggest that profiles B and C confer a higher
relative risk of a bad outcome than other proven prognostic
variables, including NYHA functional class (6). However,
the basis for the prognostic value of clinical profiles remains
unclear.
It is possible that clinical profiles are surrogates for the
duration of HF. However, in this cohort there was no
correlation between the original diagnosis of HF and time
to hospitalization for decompensation, suggesting that pro-
files A, B, and C do not represent a sequential progression
in disease severity.
Several studies have shown that hemodynamics predict
outcomes in patients with chronic HF (13–16). The small
subset of patients who underwent right heart catheterization
in this study suggests that clinical profiles may derive
prognostic value because they reflect invasive hemodynamic
measurements. Several clinical features reliably predict he-
modynamic derangements in chronic HF. Orthopnea accu-
rately predicts increased PCWP in 91% of patients with
chronic HF (4). Positive hepatojugular reflux also correlates
well with elevated PCWP in chronic HF (17–19). An
abnormal arterial blood pressure response to the Valsalva
maneuver predicts elevated PCWP with a sensitivity of 92%
to 100% and a specificity of 83% to 91% (20,21). Addition-
ally, a proportional pulse pressure 25% strongly parallels
hemodynamic evidence of hypoperfusion (CI 2.2 l/min/
m2) (4,22). Because the determination of clinical profiles
involves integration of multiple physical findings, clinical
profiles may provide a more reliable estimate of invasive
hemodynamics than any one sign alone.
A previous study (22) comparing retrospectively assigned
clinical profiles to invasive hemodynamics showed that
patients with a “wet” profile tended to have higher PCWP
than those with a “dry” profile. Similarly, patients with a
“cold” profile tended to have lower CI than patients with a
“warm” profile. Although outcomes did not differ signifi-
cantly between the various clinical profiles (22), the trend
for survival was similar to that seen in the present analysis.
Table 3. Univariate Predictors of One-Year Mortality Plus
Urgent Transplantation
Variables
Hazard
Ratio (95% CI) p Value
Profile A Reference — —
Profile B 2.10 (1.29–3.43) 0.003
Profile C 3.66 (2.16–6.21)  0.001
Profile L 1.98 (0.75–5.24) 0.17
Age 1.03 (1.02–1.04)  0.001
Female gender 0.84 (0.58–1.22) 0.36
Ischemic cardiomyopathy 1.90 (1.35–2.68)  0.001
Treatment with ACEI 0.73 (0.51–1.05) 0.09
Treatment with beta-blockers 0.92 (0.62–1.36) 0.68
Ejection fraction 0.99 (0.99–1.01) 0.40
NYHA functional class 1.51 (1.23–1.85)  0.001
Resting heart rate 1.00 (0.99–1.01) 0.65
Systolic blood pressure 0.99 (0.98–1.00) 0.01
Serum sodium 0.95 (0.92–0.98) 0.001
Serum creatinine 1.27 (1.16–1.40)  0.001
ACEI  angiotensin-converting enzyme inhibitor; CI  confidence interval;
NYHA  New York Heart Association.
Table 4. Multivariate Analysis of the Variables Associated With One-Year Mortality Plus
Urgent Transplantation
Variables
All Patients NYHA III/IV
Hazard
Ratio p Value
Hazard
Ratio p Value
Profile A Reference — Reference —
Profile B 1.83 0.02 2.23 0.03
Profile C 2.48 0.003 2.73 0.009
Profile L 1.94 0.19 1.94 0.28
Age 1.02 0.001 1.02 0.004
Ischemic cardiomyopathy 1.52 0.03 1.34 0.15
NYHA functional class 1.25 0.06 1.35 0.13
Systolic blood pressure 0.99 0.09 0.99 0.09
Serum sodium 0.98 0.22 0.99 0.49
Serum creatinine 1.38  0.001 1.46  0.001
NYHA  New York Heart Association.
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Retrospective assignment of profiles and frequent intrave-
nous inotrope use might have made the identification of
significant mortality differences between the clinical profiles
difficult in the prior study.
Clinical evidence of elevated filling pressures has previ-
ously been shown to predict outcomes in HF. A recent
report demonstrated that the presence of an elevated jugular
venous pressure and S3 was associated with an increased risk
of hospitalization and death among patients enrolled in the
Studies Of Left Ventricular Dysfunction (SOLVD) treat-
ment trial (23). Another study evaluating patients four to six
weeks after treatment for NYHA class IV symptoms also
showed that persistent evidence of congestion predicted
worse outcomes in patients with chronic HF (24). Further-
more, objective exercise limitation, which predicts outcomes
in patients with chronic HF (25), has also been shown to
correlate with physical findings of congestion (26). These
results reinforce the value of evaluating disease severity by
means of a simple bedside clinical evaluation.
The use of clinical profiles to guide therapy. Although
not routinely measured, these data suggest that clinical
profiles may provide a qualitative estimate of hemodynamics
at the bedside. In the absence of more rigorous evidence,
these profiles may help guide therapy. Profile A (dry-warm)
described a group of well-compensated patients with a good
overall prognosis. Yet, one-third (38/123) of patients with
profile A presented with symptoms of decompensated HF,
and presentation with profile A may prompt a search for
other causes of dyspnea. Because symptom relief and low-
ering of filling pressures is the immediate goal of therapy in
patients with profile B (wet-warm), they may be diuresed
empirically, with or without enhanced vasodilation. Con-
versely, patients with profile C (wet-cold) might require
hospitalization for more intensive therapy to achieve ade-
quate diuresis, perhaps even guided by serial invasive hemo-
dynamic measurements. A recent trial evaluating the effects
of short-term milrinone on length of hospitalization and
60-day mortality showed that routine use of inotropic
therapy in patients with NYHA class III/IV symptoms
results in increased short-term morbidity (1). It is possible
that profile C may identify a subset of patients within those
with NYHA class III/IV symptoms in whom the risk-
benefit ratio of short-term inotropic therapy differs.
Clinical profiling may also help guide titration of beta-
blocker therapy. Patients with profile A may tolerate initi-
ation and up-titration of beta-blockers with the success
observed in major trials, whereas profile B might represent
a population where chronic beta-blocker therapy could be
maintained but initiation or up-titration deferred until
restoration of profile A. Conversely, determination of pro-
file C might lead to a decrease or withdrawal of recently
initiated beta-blockers until better compensation is
achieved. The greater use of beta-blockers on admission in
patients with profile A relative to those with profiles B and
C is consistent with this management strategy.
The prognostic information provided by clinical profiles
may also help guide listing for transplantation in patients
where oxygen consumption measures do not provide an
obvious mortality benefit with transplantation (25). In this
cohort, the mean peak oxygen consumption ranged from 10
to 14 ml/kg/min, regardless of clinical profile. Thus, in
hospitalized patients who are too sick to do an exercise stress
test or whose last reported oxygen consumption does not
reflect their present clinical status, clinical profiles may be
useful.
Although we propose ways in which clinical profiles
might be used to guide the treatment of chronic HF, there
are no data to support their utility for this indication. This
question will be partially addressed by the ongoing multi-
center Evaluation Study of Congestive Heart Failure and
Pulmonary Artery Catheterization Effectiveness (ES-
CAPE) evaluating the correlation of clinical profiles to
hemodynamic measurements and the success of clinical
assessment-based versus catheter-guided therapy (27).
Similar to prior reports (4,22), profile L (dry-cold) was
uncommon in this cohort. This grouping probably repre-
sents the few patients with HF who have significantly
reduced cardiac reserve with a decreased tendency towards
congestion. Alternatively, it might describe patients with
severely dilated ventricles and anatomic mitral regurgitation
who develop symptoms with minimal exertion. Patients
with profile L, in particular, may benefit from interventions
such as biventricular pacing, mitral valve repair, and surgical
ventricular remodeling aimed at improving myocardial effi-
ciency.
Figure 3. Kaplan-Meier survival curves according to the clinical profiles in
patients with New York Heart Association functional class III/IV heart
failure. The end point shown is one-year mortality  urgent transplanta-
tion. Patients with profiles B and C had worse outcomes than profile A.
Profile L had too few patients for meaningful statistical analysis. The
survival for profiles B and C did not differ significantly after Bonferroni
correction. *p  0.015 for profile A versus profile B, †p  0.04 for profile
B versus profile C, ‡p  0.001 for profile A versus profile C.
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Use of clinical profiles to identify patient populations for
research studies. Although the mortality for mild to mod-
erate HF, as defined by NYHA classification, is fairly
consistent across trials, advanced HF represents a heteroge-
neous group of patients with annual mortality estimates
ranging from 17% in the beta-blocker trials (28,29) to 75%
in the recent LVAD trial (2). This heterogeneity holds true
even when restricted to trials of patients hospitalized with
advanced HF (Table 5). In this study, whereas the majority
of patients with NYHA class III/IV symptoms had profiles
B and C, a substantial number had profile A and a relatively
good prognosis. A comparison of mortality estimates in
large clinical trials of advanced HF to survival for the
different clinical profiles suggests that profile A has a similar
mortality as the beta-blocker trials (28,29) and profile B to
that reported in trials of oral and intravenous inotropic
therapy (28,30). The mortality for profile C is similar to that
described in the trial of epoprostenol in patients with
documented CI 2.2 l/min/m2 and PCWP 15 mm Hg
and approaches the early mortality seen in the Randomized
Evaluation of Mechanical Assistance for the Treatment of
Congestive Heart Failure (REMATCH) trial (2) (Table 5).
Clinical profiles therefore further stratify patients with
advanced HF and could be used to refine inclusion criteria
for the selection of patients for investigational therapies.
Study limitations. This analysis has several potential lim-
itations. The results of this single-center study might not be
replicated in other settings with less attention to the
physical examination. However, in this study, physicians at
various levels assessed the clinical profiles, suggesting that
these findings might be generalized to others dedicated to
the care of this population.
Although physicians were instructed to base their assess-
ment of clinical profiles on the physical examination, other
factors such as patient distress or abnormal laboratory values
might have influenced their decisions. This potential source
of bias has been diminished by controlling for other clinical
and laboratory predictors of mortality in the multivariable
analysis. Furthermore, the finding that clinical profiles were
useful even among patients with NYHA class III/IV symp-
toms suggests that knowledge of functional capacity did not
negate the value of bedside clinical evaluation.
The decision to list patients for transplantation may have
been influenced by the clinical profile assessment. Analyses
using the end point of death in addition to the combined
end points of death and urgent transplantation were there-
fore performed. The ability of clinical profiles to predict
both death and death plus urgent transplantation makes it
unlikely that the end points were biased by initial profile
observations.
The clinical profiles were not routinely compared to
invasive hemodynamic measurements. Many patients did
not undergo right heart catheterization or had it performed
after initial diuresis to relieve obvious volume overload.
Whether clinical profiles only reflect hemodynamics or also
integrate other features of circulatory compromise, classifi-
cation by clinical profiles provides an important prognostic
tool that can be used quickly, conveniently, and more
repeatedly than right heart catheterization.
CONCLUSIONS
This study of clinical profiles reaffirms the value of clinical
assessment in the daily practice of cardiology, which in-
creasingly includes chronic HF. Clinical profiles are easy to
define, predict prognosis, and appear to do so better than
traditional markers of disease severity. These profiles may be
useful to guide therapy and to select appropriate patients for
clinical trials, particularly those designed for patients with a
poor prognosis on current medical therapy.
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